Af­fimed nar­rows PhI/IIa fo­cus; Bris­tol My­ers pays Agenus $25M; Mer­ck, Mod­er­na start an­oth­er PhI­II can­cer vac­cine

Plus, news on No­var­tis’ re­cent­ly-ap­proved ip­ta­co­pan and Acurx’s an­tibi­ot­ic.

Af­fimed drops some in­di­ca­tions from PhI/IIa tri­al: As the biotech re­ports promis­ing mid-stage da­ta for its in­nate cell en­gager AFM24 in non-small cell lung can­cer, the com­pa­ny has de­cid­ed to cut off en­roll­ment in the oth­er co­horts of the tri­al to stay fo­cused. That in­cludes a gas­tric can­cer co­hort and a bas­ket co­hort in pan­cre­at­ic can­cer, bil­iary tract can­cer and he­pa­to­cel­lu­lar car­ci­no­ma, which showed some clin­i­cal ac­tiv­i­ty that was, how­ev­er, un­like­ly to meet its bar, Af­fimed said. The tri­al was test­ing AFM24, which binds to EGFR and CD16A, in com­bi­na­tion with Roche’s PD-L1 in­hibitor Tecen­triq in EGFR-ex­press­ing sol­id tu­mors. — Am­ber Tong

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER